611 results on '"Dienstmann, R."'
Search Results
2. The TEOGIC study project: a comprehensive characterization of early onset gastrointestinal cancer in the Northern area of Spain
3. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
4. ESMO Recommendations on clinical reporting of genomic test results for solid cancers
5. ESMO Guidance for Reporting Oncology real-World evidence (GROW)
6. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments
7. Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer
8. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer
9. 29O Clinical characterization of long-term survivors in phase I clinical trials
10. 93P Evolving landscape of targeted therapies (TT) in early phase clinical trials (EPCT): The RESISTANCE project (360R)
11. Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network
12. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
13. Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients
14. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer
15. RWD12 Wayfind-R: A Global, Real-World Precision Oncology Registry – Socioeconomic Features
16. EP03.06-06 KRAS-B: Molecular Epidemiology and Clinical Outcomes of KRAS-Mutant Non-small Cell Lung Cancer (NSCLC) in Brazil
17. ESMO Guidance for Reporting Oncology real-World evidence (GROW)
18. Time to start testing KRAS and BRAF V600E mutations in stage III colon cancer? Not in routine care, yet in clinical trials
19. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients
20. Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients
21. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2
22. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer
23. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
24. Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study
25. ESMO Guidance for Reporting Oncology real-World evidence (GROW)
26. 43P MDM2 alterations in primary brain tumors: A potential niche for targeted therapy
27. 160P COLUMBIA-1: A phase Ib/II, open-label, randomized, multicenter study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab as first-line (1L) therapy in metastatic microsatellite-stable colorectal cancer (MSS-mCRC)
28. 88P Next-generation sequencing (NGS) in routine care: Medical practice in 24 countries from the pan-cancer WAYFIND-R registry.
29. EP04.01-022 Real-world Evidence of Durvalumab for Stage III NSCLC: Survival Outcomes and Patterns of Care Post-progression
30. EP08.02-056 Coexisting MET Exon 14 Skipping Mutation and MET Amplification in a Patient with Complete Response to MET Inhibitors
31. EP07.01-023 Family History of Cancer in a Series of Malignant Pleural Mesothelioma (MPM) Patients (P)
32. 686P Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
33. 702P Genomic alterations in epigenetic modifiers and response to epigenetic-targeted agents (ETAs) in patients (pts) with recurrent/metastatic (R/M) salivary gland tumours (SGTs)
34. EP07.01-022 Analysis of Second Surgery for Recurrence in Malignant Pleural Mesothelioma (MPM) Patients (P)
35. 290P Potential enrichment strategies for next-generation sequencing (NGS) in primary brain cancers (pBCs) in a clinical series according to ESMO scale for clinical actionability of molecular targets (ESCAT)
36. 1557MO Phase II trial evaluating effect of gonyautoxins (GTX), a paralytic shellfish poisoning (PSP) on objective and subjective symptoms of chemotherapy-induced peripheral neuropathy (CIPN)
37. 1637P Impact of immune-related adverse events (irAEs) and survival (OS) in a cohort of MPM patients (p) treated with immunotherapy (IT)
38. Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial
39. Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
40. Reply to the letter to the editor ‘Including lynch syndrome in personalized prognostication and follow-up of stage II and III colon cancer’ by Sciallero et al.
41. 211P Assessment of the financial toxicity after oncological treatment in patients with breast cancer in private oncological reference institutions in Brazil
42. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
43. WS04.02 Access to Biomarker Testing in Latin America
44. MA04.07 Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection
45. 445P Tumor load surrogates as major prognostic factors in BRAF-V600E mutated (mt) colorectal (CRC) patients treated with BRAF inhibitor+antiEGFR +/- MEK inhibitor
46. 1697TiP Evaluation of gonyautoxins (GTX) on objective and subjective symptoms of chemotherapy-induced peripheral neuropathy (CIPN)
47. 1733P Analysis of chemotherapy (Ct) efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p)
48. 426P Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care
49. 461P Molecular tumor profiling and matched molecular targeted treatment in metastatic young-onset colorectal cancer (YOCR)
50. 1577P Early mortality linked to COVID-19 in cancer patients as compared to historical control in pre-pandemic times
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.